A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006

被引：0

作者：

Hashimoto, Tadayoshi ^{[1
]}

Maruyama, Satoshi ^{[2
]}

Takii, Yasumasa ^{[2
]}

Mizusawa, Junki ^{[1
]}

Kataoka, Tomoko ^{[1
]}

Fukuda, Haruhiko ^{[1
]}

Tsukamoto, Shunsuke ^{[3
]}

Takashima, Atsuo ^{[4
]}

Hamaguchi, Tetsuya ^{[5
]}

Kanemitsu, Yukihide ^{[3
]}

Colorectal Canc Study Grp, Colorectal Canc Study Grp

Japan Clinical Oncology Grp, Japan Clinical Oncology Grp

机构：

[1] Natl Canc Ctr, Japan Clin Oncol Grp, Operat Off, Data Ctr, Tokyo, Japan

[2] Niigata Canc Ctr Hosp, Dept Surg, Niigata, Japan

[3] Natl Canc Ctr, Dept Colorectal Surg, Tokyo, Japan

[4] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan

[5] Saitama Med Univ Int Med Ctr, Dept Gastroenterol Oncol, Hidaka, Japan

来源：

FUTURE ONCOLOGY | 2023年 / 19卷 / 28期

关键词：

colon cancer; FOLFOXIRI; locally advanced; mFOLFOX6; preoperative chemotherapy; selection design; METASTATIC COLORECTAL-CANCER; COMPUTED-TOMOGRAPHY; 1ST-LINE TREATMENT; FLEXIBLE DESIGN; RECTAL-CANCER; OPEN-LABEL; OXALIPLATIN; FOLFIRI; CLASSIFICATION; CHEMOTHERAPY;

D O I：

10.2217/fon-2023-0091

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prognosis of locally advanced colon cancer (LACC) with surgical resection followed only by adjuvant chemotherapy is poor. Preoperative chemotherapy for LACC patients with risk factors such as cT4bN+ or cT3-4aN2-3 has attracted attention. Here, the authors describe the rationale and design of JCOG2006, a randomized phase II study comparing preoperative chemotherapy with mFOLFOX6 versus FOLFOXIRI for LACC. Their efficacy and safety are evaluated and a determination of which is the more promising treatment will be conducted in a subsequent phase III trial. A total of 86 patients will be accrued from 44 institutions over 2 years. The primary end point is the proportion of patients with a Tumor Regression Score of 0-2, and secondary end points include overall survival, response rate and adverse events.Clinical Trial Registration: jRCTs031210365 (https://jrct.niph.go.jp/) A randomized phase II selection design trial for resectable locally advanced colon cancer to determine whether mFOLFOX6 or FOLFOXIRI is more promising for a subsequent phase III trial.

引用

页码：1897 / 1904

页数：8

共 50 条

[41] A randomized phase II study evaluating efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy for patients with resectable rectal cancer (KSCC1301).
Katsumata, Kenji
Oki, Eiji
Kato, Hiroyuki
Miwa, Keisuke
Sugiyama, Masahiko
Murakami, Hidetsugu
Hasegawa, Hiroshi
Mori, Shinichiro
Nakayama, Goro
Saeki, Hiroshi
Shimokawa, Mototsugu
Kakeji, Yoshihiro
Baba, Hideo
Akagi, Yoshito
Maehara, Yoshihiko
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[42] Phase II clinical trial of adjuvant chemotherapy with mFOLFOX6/XELOX for stage III colon cancer in Japanese subjects
Yamada, T.
Koda, K.
Ishibashi, K.
Kato, H.
Nishimura, G.
Ooki, S.
Yoshimatsu, K.
Uchida, E.
Kan, H.
Kosugi, C.
Tanaka, S.
Kato, R.
Kouketsu, S.
Nakajima, H.
Maekawa, H.
Kobayashi, M.
Tsubaki, M.
Yokoyama, M.
Tanakaya, K.
Ishida, H.
ANNALS OF ONCOLOGY, 2015, 26 : 55 - 55
[43] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
van Hazel, Guy A.
Heinemann, Volker
Sharma, Navesh K.
Findlay, Michael P. N.
Ricke, Jens
Peeters, Marc
Perez, David
Robinson, Bridget A.
Strickland, Andrew H.
Ferguson, Tom
Rodriguez, Javier
Kroening, Hendrik
Wolf, Ido
Ganju, Vinod
Walpole, Euan
Boucher, Eveline
Tichler, Thomas
Shacham-Shmueli, Einat
Powell, Alex
Eliadis, Paul
Isaacs, Richard
Price, David
Moeslein, Fred
Taieb, Julien
Bower, Geoff
Gebski, Val
Van Buskirk, Mark
Cade, David N.
Thurston, Kenneth
Gibbs, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
[44] A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases: WJOG10517G
Hara, H.
Masuishi, T.
Ando, T.
Kawakami, T.
Yamamoto, Y.
Sugimoto, N.
Shiraishi, K.
Esaki, T.
Negoro, Y.
Tsuzuki, T.
Sawai, H.
Nakamura, M.
Inagaki, T.
Shinohara, Y.
Kawakami, H.
Kawakami, K.
Katsuya, H.
Maeda, O.
Fujita, Y.
Yoshimura, K.
Nakajima, T.
Muro, K.
ANNALS OF ONCOLOGY, 2022, 33 : S284 - S285
[45] Phase II study in progress to verify mproved response with mFOLFOX6 after exposure to an immune checkpoint inhibitor in advanced gastric cancer
Ann, H.
Manaka, D.
Konishi, S.
Ikeda, Y.
Ora, T.
Kudo, I.
Kawaguchi, K.
Sasaki, N.
Hamasu, S.
Nishitai, R.
ANNALS OF ONCOLOGY, 2019, 30
[46] Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study)
Chihiro Kosugi
Keiji Koda
Keiichiro Ishibashi
Kazuhiko Yoshimatsu
Soichi Tanaka
Ryouji Kato
Hiroyuki Kato
Masatoshi Oya
Kazuo Narushima
Mikito Mori
Kiyohiko Shuto
Hideyuki Ishida
International Journal of Colorectal Disease, 2018, 33 : 809 - 817
[47] A Phase I/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer
Van Cutsem, E.
Prenen, H.
Guillen-Ponce, C.
Bennouna, J.
Di Benedetto, M.
Bouche, O.
Staines, H.
Oum'Hamed, Z.
Studeny, M.
Capdevila, J.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : 8 - 9
[48] Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study)
Kosugi, Chihiro
Koda, Keiji
Ishibashi, Keiichiro
Yoshimatsu, Kazuhiko
Tanaka, Soichi
Kato, Ryouji
Kato, Hiroyuki
Oya, Masatoshi
Narushima, Kazuo
Mori, Mikito
Shuto, Kiyohiko
Ishida, Hideyuki
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (06) : 809 - 817
[49] mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials
Zhang, J.
Deng, Y.
Wu, Z.
Hu, H.
Cai, Y.
Ling, J.
ANNALS OF ONCOLOGY, 2018, 29
[50] mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials
Zhang, J.
Hu, H.
Wu, Z.
Cai, Y.
Ling, J.
Xiao, J.
Deng, Y-H.
ANNALS OF ONCOLOGY, 2018, 29 : 28 - 28

← 1 2 3 4 5 →